康辰藥業(603590.SH):將根據項目優先順序和項目進度 用於創新藥CX1003、CX1026的項目研發及靶向抗腫瘤藥物創新平台建設
格隆匯3月12日丨康辰藥業(603590.SH)披露變更募集資金投資項目部分投資規劃,原項目名稱:創新藥研發及靶向抗腫瘤藥物創新平台建設項目;
項目變更內容:創新藥研發及靶向抗腫瘤藥物創新平台建設項目的投資規劃之一“CX1409研發項目”擬終止
變更募集資金投向的金額:CX1409研發項目原計劃投資總額約2.45億元,截至2020年2月29日,該項目累計投入研發費用1949.99萬元,已使用募集資金(含已置換預先投入自籌資金金額)98.23萬元,項目終止後,“創新藥研發及靶向抗腫瘤藥物創新平台建設項目”投資總額仍然高於公司實際擬投入募集資金金額41142.5937萬元,因此該項目實際募集資金將根據項目優先順序和項目進度,用於創新藥CX1003、CX1026的項目研發及靶向抗腫瘤藥物創新平台建設,項目投資總額不足部分由公司以自籌資金投入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.